Tissue Regeneration by Engineered Extracellular Vesicles

工程细胞外囊泡的组织再生

• 批准号: 10021673
• 负责人: James D. Bryers
• 金额: $ 46.01万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-20 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10021673
• 关键词: Angiogenic Factor; B-Lymphocytes; Biocompatible Materials; Biological Assay; C57BL/6 Mouse; CD19 gene; CD3 Antigens; Cell Line; Cell Lineage; Cell Therapy; Cell membrane; Cells; Chronic; Coated vesicle; Communication; Defect; Encapsulated; Engineering; Epigenetic Process; Ethical Issues; Exhibits; Fibroblasts; Film; Fingerprint; Flow Cytometry; Fluorescence; Foreign Bodies; Gene Expression; Genetic Transcription; Growth; Growth Factor; ITGAX gene; Implant; In Vitro; Inflammation; Knockout Mice; Lipids; Mass Spectrum Analysis; Mediating; Membrane; Membrane Proteins; Mesenchymal Stem Cells; Messenger RNA; MicroRNAs; Modeling; Mouse Strains; Myelogenous; Myeloid Cells; Natural regeneration; Nucleic Acids; Organ Transplantation; Parents; Pathway interactions; Phenotype; Polymers; Proteins; Research; Role; Signal Transduction; Somatic Cell; Spinal cord injury; Stains; Structure; Surface; System; T-Lymphocyte; TLR1 gene; Technology; Testing; Time; Tissues; Transgenic Mice; Tube; United States National Institutes of Health; Vesicle; Work; Wound models; angiogenesis; biodegradable polymer; bone; culture plates; cytokine; embryonic stem cell; engineered exosomes; exosome; experimental study; extracellular vesicles; healing; in vivo; injured; intercellular communication; macrophage; microvesicles; novel; paracrine; particle; preservation; proteomic signature; regenerative; release factor; response; scaffold; selective expression; stem cell therapy; stem cells; stem-like cell; tissue regeneration; tissue repair; tissue support frame; transcription factor; transdifferentiation; vesicular release

Summary Worldwide stem cell therapy market is poised to grow at a compound annual growth rate (CAGR) of 39.5% from 2015 to 2020, reaching US$330M by 2020. However, limitations such as: (1) ethical issues related to embryonic stem cells, (2) difficulties related with the preservation of stem cells, and (3) recent research findings that the structural contribution of stem cells to regenerated tissues is actually very small, are starting to compromise the promised potential of stem-cell based therapies. Recent research has thus shifted away from cell based therapy to a paracrine hypothesis, investigating the stimulating factors released and received by cells, including: growth factors, cytokines, and extracellular vesicles (EVs; i.e., exosomes and microvesicles containing angiogenic factors, transcription factors, miRNAs). Work proposed here will determine whether myeloid cells, i.e., can be engineered to differentiate (or trans-differentiate) into desired non-myeloid lineages through an orchestrated engineering of EV exchange within our novel biomaterials platform.

摘要 全球干细胞治疗市场有望以39.5%的复合年增长率(CAGR)增长 从2015年到2020年，到2020年达到3.3亿美元。然而，限制例如：(1)与以下有关的伦理问题 胚胎干细胞，(2)与干细胞保存有关的困难，以及(3)最近的研究 研究发现，干细胞对再生组织的结构性贡献实际上非常小， 开始损害基于干细胞的疗法的承诺潜力。最近的研究表明 从基于细胞的治疗转向旁分泌假说，研究刺激因素 由细胞释放和接收的，包括：生长因子、细胞因子和细胞外小泡(EV；即， 含有血管生成因子、转录因子、miRNAs的外切体和微囊)。建议的工作 这将决定髓系细胞是否可以被工程分化(或转分化)为 在我们的小说中通过精心策划的EV交换来获得所需的非髓系血统 生物材料平台。